<< WASHINGTON, Feb 28 (Reuters) - Biogen Idec (BIIB.O: Quote, Profile, Research) insiders reaped millions in cash bonuses and stock sales shortly before the company informed regulators of safety concerns regarding its new blockbuster multiple sclerosis drug, regulatory filings show.
On Feb. 17, the day before Biogen provided the U.S. Food and Drug Administration information on a patient death and another serious injury from its Tysabri drug, the company's board of directors approved $4.6 million in 2004 executive cash bonuses, according to a filing with the U.S. Securities and Exchange Commission.
On Feb. 18, the same day as the company's FDA notification, Biogen General Counsel Thomas Bucknum sold 89,700 shares for a profit of $1.94 million, according to an SEC filing.
On Feb. 15, three days before the company's notification to the FDA, Biogen Executive Chairman William Rastetter sold 120,313 shares for a profit of $7.45 million, in accordance with a previously filed trading plan, SEC filings show. >>
<< SEC filings also show that on Feb. 14, Biogen director Robert Pangia sold 15,570 shares for a $954,844 profit, also in accordance with a previously filed trading plan.
Biogen's spokesman denied that either Rastetter or Pangia had knowledge of Tysabri safety concerns prior to the trades. (ed. well they sure weren't going to ADMIT it! >>
more .....
http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh53001_2005-03-01_01-13-40_n28305650_newsmlDon't tell me its not all about money, please don't tell me this.
How many have and will die? How many?
:grr: :grr: :grr: